Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program

-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

CAMBRIDGE, Mass., February 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic scholarships of up to $5,000 will be awarded to up to 20 individuals chosen by an independent committee of Duchenne community members based on an applicant's community involvement and personal essay. The Route 79 program is designed to help students with Duchenne pursue their post-secondary educational goals.

"In 2018, we launched Route 79, The Duchenne Scholarship Program, supporting the educational goals of students living with Duchenne," said Douglas Ingram, Sarepta's president and chief executive officer. "The response to Route 79 has been overwhelming and the quality of applications from our first year of the program was very impressive. Once again this year we are excited to receive and evaluate applications from ambitious students who would benefit from Route 79."

The underlying cause of Duchenne is a mutation or error in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship's name, Route 79, ties to the 79 exons of the dystrophin gene.

To apply for a scholarship through the Route 79 program, applicants must be accepted to or enrolled into an accredited college or university or a trade, technical or vocational school located in the United States and be diagnosed with Duchenne muscular dystrophy.[i] Receipt of Route 79 scholarship funds for the 2018-2019 academic year will not preclude students from applying for the scholarship for the 2019-2020 academic year.

Applications will be accepted until April 30, 2019 at 11:59 PM PT. Recipients will be announced prior to August 2019 and awards will be distributed by mid-August, in time for fall 2019 enrollment. Students may apply by clicking here.

[i] *No consideration will be given to whether or not an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational product.*

About Sarepta Therapeutics

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (Duchenne) and more recently in gene therapies for 5 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com